Vapourtec’s R-Series flow chemistry system, equipped with a UV-150 photochemical reactor, has been cited in research by scientists* at Novo Nordisk in the C-terminal α-amination of peptides and ...

The GLP-1 liraglutide showed potential benefit in reducing ... Presented at: International Stroke Conference; Feb. 5-7, 2025; Los Angeles (hybrid meeting). LAMP was a multicenter, randomized ...

Over a mean 2.2 years, the GLP1-RA group had significantly lower annual rates of acute healthcare utilization per patient (1.52 vs 1.67 events) and all-cause deaths (17.7 ... 36% lower with GLP ...

Related Cosmetic surgeons try to correct 'Ozempic face' for weight-loss drug users Massive study looks at benefits, risks of GLP-1 weight-loss ... hospital care and 36% less apt to see their ...

Folks who took one of the latter class of drugs were 16% less likely to die, 10% less likely to need hospital care and 36% less apt to see their kidney disease progress, compared to patients ...

Roche has reported early-stage clinical data with an oral GLP-1 agonist ... from a phase 1 trial of a once-daily pill called CT-966, which revealed an average weight loss of 7.3% at four weeks ...

The drugs, known as GLP-1 receptor agonists, work by mimicking hormones in the gut and the brain to regulate appetite and feelings of fullness. The new study looked at one of these drugs ...

Scientists at Novo Nordisk have demonstrated a photochemically enabled strategy for the functionalisation of peptides and ...

GLP-1: Glucagon-like peptide-1 ... Semaglutide resulted in more patients reaching A1c target of <7%, and significantly more average weightloss, than liraglutide once daily. LA GLP1-RAs have ...